Lambert-Eaton Myasthenic Syndrome (LES)

NEWS

Amifampridine, CAS# 54-96-6 is the first and only approved drug thus far for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome in adults. As a rare autoimmune disease, Lambert-Eaton Myasthenic Syndrome, also called LEMS, is typically caused by  auto antibodies  to voltage gated calcium channels, leading to a reduction in the amount of acetylcholine released from nerve terminals in patients. The predominant symptom of LEMS is muscle weakness, with this weakness usually concentrated in the proximal muscles of the legs and trunk. Additional, devastating symptoms of this rare disease include extreme fatigue, reduced reflexes, drooping of the eyelids, problems with swallowing,